Biogen Ma Inc. v. Emd Serono, Inc., 19-1133 (2020)
Court: Court of Appeals for the Federal Circuit
Number: 19-1133
Visitors: 4
Filed: Nov. 20, 2020
Latest Update: Nov. 21, 2020
Case: 19-1133 Document: 98 Page: 1 Filed: 11/20/2020 United States Court of Appeals for the Federal Circuit ______________________ November 20, 2020 ERRATA ______________________ Appeal No. 2019-1133 BIOGEN MA INC., Plaintiff -Appellee v. EMD SERONO, INC., PFIZER INC., Defendants-Appellants BAYER HEALTHCARE PHARMACEUTICALS INC., NOVARTIS PHARMACEUTICALS CORPORATION, Defendants Decided: September 28, 2020 Precedential Opinion ______________________ Please make the following changes: On page 8, lines 17–20, change “emphasized that whereas the attached carbohydrate groups in na- tive IFN-β protein were glycosolated, the attached carbohydrate groups in recombinant IFN-β were not glycosolated,” to —explained that the glycosyl- ation patterns in native IFN-β and recombinant IFN-β were different,—.
Source: CourtListener
